Share This Article:

Greenlight Photoselective Vaporisation of the Prostate in 133 High Surgical Risk Patients: A 5-Year Outcome Study

Abstract Full-Text HTML Download Download as PDF (Size:220KB) PP. 90-95
DOI: 10.4236/oju.2013.32018    3,597 Downloads   5,184 Views   Citations

ABSTRACT

Greenlight photoselective vaporisation of the prostate (GPVP) is progressively becoming an established treatment in patients with LUTS because it is a minimally invasive technique that achieves efficient haemostasis, making it the ideal technique for patients at high surgical risk. Material and Methods: To study of 133 patients with an ASA surgical risk score of 3 or 4, undergoing GPVP, with an analysis of perioperative outcome, IPSS, Qmax, IIEF-5 and complications during a five-year follow-up. Results: At 5 years the mean annual improvement in IPSS was stable, and at 5 years there was a 15.2 point improvement versus the preoperative score (p < 0.05). The Qmax showed an improvement of 14.9 ml/sec and was maintained at five years after surgery (p < 0.05). No patients were transfused or suffered urinary incontinence. 2.25% suffered major complications and there were no deaths. 3.1% of patients suffered de novo urgency. In the 5-year follow-up, five patients had to be reoperated. The quality of sexual health assessed by IIEF-5 before the procedure was scored at 14 points; the 5-year follow-up covering the preoperative period and all revisions did not show any worsening in the IIEF-5 score (p > 0.05). Conclusions: Due to its physical characteristics, in our opinion GPVP is now the treatment of choice in patients at high surgical risk. In our series, the risk of major/minor complications and transfusions was much lower than the same risks in conventional techniques. The objective results (Qmax and quality of life questionnaire) are equivalent to conventional techniques and persist over a 5-year follow-up.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

I. García, M. Molina, E. Hidalgo, L. Buitrago, N. Betancourt, L. Lara, P. Gutierrez, A. Crespo, F. Férnandez and A. Rodríguez, "Greenlight Photoselective Vaporisation of the Prostate in 133 High Surgical Risk Patients: A 5-Year Outcome Study," Open Journal of Urology, Vol. 3 No. 2, 2013, pp. 90-95. doi: 10.4236/oju.2013.32018.

References

[1] C. Capitán Manjon, J. M. de la Morena, E. de la Pena, et al., “Papel Actual de la Fotovaporización Prostática con Láser Greenlight HPS. Aspectos téCnicos y Revisión de la Literatura,” Actas Urológicas Espa?olas, Vol. 33, No. 7, 2009, pp. 771-777. doi:10.1016/S0210-4806(09)74230-5
[2] X. Yu, S. P. Elliott, T. J. Wilt, et al., “Practice Patterns in Benign Prostatic Hyperplasia Surgical Therapy: The Dramatic Increase in Minimally Invasive Technologies,” The Journal of Urology, Vol. 180, No. 1, 2008, pp. 241-245. doi:10.1016/j.juro.2008.03.039
[3] G. Alivizatos and A. Skolarikos, “Greenlight in Benign Prostatic Hyperplasia: Turning Green into Gold,” Current Opinion in Urology, Vol. 18, 2008, pp. 46-49. doi:10.1097/MOU.0b013e3282f0d63b
[4] P. Sountoulides, O. Kaufmann, D. Kikidakis, et al., “Vaporización Fotoselectiva de la Próstata (VFP) vs Enucleacion de la Próstata Con Laser Holmio (HoLEP): Resultados Actuales y Estrategias,” Archivos Espanoles de Urología, Vol. 63, No. 2, 2010, pp. 89-101. doi:10.4321/S0004-06142010000200001
[5] W. J. Fu, B. F. Hong, X. X. Wang, et al., “Evaluation of Greenlight Photoselective Vaporization of the Prostate for the Treatment of High Risk Patients with Benign Prostatic Hyperplasia,” Asian Journal of Andrology, Vol. 8, 2006, pp. 367-371. doi:10.1111/j.1745-7262.2006.00134.x
[6] A. E. Te, T. R. Malloy, B. S. Stein, et al., “Photoselective Vaporization of the Prostate for the Treatment of Benign Prostatic Hyperplasia: 12 Months Results from the First United States Multicenter Prospective Trial,” The Journal of Urology, Vol. 172, No. 4, 2004, pp. 1404-1408. doi:10.1097/01.ju.0000139541.68542.f6
[7] O. F. Karatas, E. Alkan, K. Horansali, et al., “Photoselctive Vaporization of the Prostate in Men with a History of Chronic Oral Anti-Coagulation,” BJU International, Vol. 36, No. 2, 2010, pp. 190-197. doi:10.1590/S1677-55382010000200009
[8] E. López Alcina, J. U. Juan Escudero, M. Fabuel Deltoro, et al., “Fotovaporización Prostática (FVP) Mediante Láser Verde. Ventajas Quirúrgicas en Pacientes de Riesgo,” Archivos Espa?oles de Urología, Vol. 61, No. 9, 2008, pp. 1029-1034. doi:10.4321/S0004-06142008000900012
[9] N. J. Parr, C. S. Loh and A. D. Desmond, “Transurethral Resection of the Prostate and Bladder Tumour without Withdrawal of Warfarin Therapy,” British Journal of Urology, Vol. 64, No. 6, 1989, pp. 623-625. doi:10.1111/j.1464-410X.1989.tb05322.x
[10] J. S. Sandhu, C. Ng, B. A. Vanderbrink, et al., “HighPower Potassium-Titanyl-Phosphate Photoselective Laser Vaporization of Prostate for Treatment for Treatment of Benign Prostatic Hyperplasia in Men with Large Prostates,” Urology, Vol. 64, No. 6, 2004, pp. 1155-1159. doi:10.1016/j.urology.2004.07.018
[11] B. V. Cleynenbreugel, S. J. Srirangam and H. Van Poppel, “High Performance System Greenlight Laser: Indications and Outcomes,” Current Opinion in Urology, Vol. 19, 2009, pp. 33-37. doi:10.1097/MOU.0b013e328317cab3
[12] H. Son, S. H. Song, J. S. Paick, “Current Laser Treatments for Benign Prostatic Hyperplasia,” Korean Journal of Urology, Vol. 51, No. 11, 2010, pp. 737-744. doi:10.4111/kju.2010.51.11.737
[13] M. Spaliviero, K. Strom, X. Gu, et al., “Does Green Light HPS Laser Photoselective Vaporization Prostatectomy Affect Sexual Function?” Journal of Endourology, Vol. 24, No. 12, 2010, pp. 2051-2057. doi:10.1089/end.2010.0296
[14] M. A. Hai, “Photoselective Vaporization of Prostate: Five Years Outcomes of Entire Clinic Patient Population,” Urology, Vol. 73, No. 4, 2009, pp. 807-810. doi:10.1016/j.urology.2008.08.502
[15] P. Sountoulides and P. Tsakiris, “The Evolution of KTP Laser Vaporization of the Prostate,” Yonsei Medical Journal, Vol. 49, No. 2, 2008, pp. 189-199. doi:10.3349/ymj.2008.49.2.189
[16] M. Spaliviero, M. Araki, D. J. Culkin, et al., “Incidence, Management, and Prevention of Perioperative Complications of Greenlight HPS Laser Photoselective Vaporization Prostatectomy: Experience in the First 70 Patients,” Journal of Endourology,, Vol. 23, No. 3, 2009, pp. 495-502. doi:10.1089/end. 2008.0299
[17] H. Son, Y. K. Ro, S. H. Min, et al., “Modified Vaporization-Resection for Photoselective Vaporization of the Prostate Using a Greenlight High-Performance System 120-W Laser: the Seoul Technique,” Urology, Vol. 77, No. 2, 2011, pp. 427-432. doi:10.1016/j.urology.2010.06.034
[18] R. Ruszat, S. Wyler, T. Forster, et al., “Safety and Effectiveness of Photoselective Vaporization of the Prostate (PVP) in Patients on Ongoing Oral Anticoagulation,” European Urology, Vol. 51, No. 4, 2007, pp. 1031-1038. doi:10.1016/j.eururo.2006.08.006
[19] H. Woo, O. Reich, A. Bachmann, et al., “Outcome of Greenlight HPS 120-W Laser Therapy in Specific Patients Populations: Those in Retention, on Anticoagulants and with Larges Prostates (≥80 ml),” European Urology Supplements, Vol. 7, No. 4, 2008, pp. 378-383. doi:10.1016/j.eursup.2008.01.016
[20] A. E. Te, T. R. Malloy, B. S. Stein, et al., “Impact of Prostate-Specific Antigen Level and Prostate Volume as Predictors of Efficacy in Photoselective Vaporization Prostatectomy: Analysis and Results of Ongoing Prospective Multicentre Study at 3 Years,” BJU International, Vol. 97, No. 6, 2006, pp. 1229. doi:10.1111/j.1464-410X.2006.06197.x
[21] A. E. Te, “The Next Generation in Laser Treatments and the Role of the Greenlight High-Perfomance System Laser,” Reviews in Urology, Vol. 8, Suppl. 3, 2006, pp. S24-S30.
[22] A. Bachmann, R. Ruszat, S. Wyler, et al., “Photoselective Vaporization of the Prostate. The Basel Experience after 108 Procedures,” European Urology, Vol. 47, No. 6, 2005, pp. 798-804. doi:10.1016/j.eururo.2005.02.003
[23] D. M. Bouchier-Hayes, P. Anderson, S. Van Appledorn, et al., “KTP Laser versus Transurethral Resection: Early Results of a Randomized Trial,” Journal of Endourology, Vol. 20, No. 8, 2006, pp. 580-585. doi:10.1089/end.2006.20.580
[24] A. Bachmann, L. Schurch, R. Ruszat, et al., “Photoselective Vaporization (PVP) versus Transurethral Resection of Prostate (TURP): A Prospective Bi-Centre Study of Perioperative Morbidity and Early Functional Outcome,” European Urology, Vol. 48, No. 6, 2005, pp. 956-972. doi:10.1016/j. eururo.2005.07.001
[25] R. Ruszat, S. Wyler, M. Seitz, et al., “Comparison of Potassium-Titanyl-Phosphate Laser Vaporization of the Prostate and Transurethral Resection of the Prostate: Update of a Prospective Non-Randomized Two-Centre Study,” BJU International, Vol. 102, No. 10, 2008, pp. 1432-1438.
[26] O. Reich, A. Bachmann, M. Siebels, et al., “High Power (80 W) Potassium-Titanyl-Phosphate Laser Vaporization of the Prostate in 66 High Risk Patients,” The Journal of Urology, Vol. 173, No. 1, 2005, pp. 158-160. doi:10.1097/01.ju.0000146631.14200.d4
[27] B. Choi, S. Tabatabaei, A. Bachmann, et al., “Greenlight HPS 120 W Laser for BHP: Comparative Complications and Technical Recommendations,” European Urology, Vol. 7, 2008, pp. 384-388. doi:10.1016/j.eursup.2008.01.013
[28] X. Yu, S. P. Elliot, T. J. Wilt, et al., “Practice Patterns in Benign Prostatic Hyperplasia Surgical Therapy: The Dramatic Increase in Minimally Invasive Technologies,” The Journal of Urology, Vol. 180, No. 1, 2008, pp. 241-245. doi:10.1016/j.juro.2008.03.039
[29] F. Bruyere, A. Puichaud, H. Pereira, et al., “Influence of Photoselective Vaporization of the Prostate on Sexual Function: Results of a Prospective Analysis of 149 Patients with Long-Term Follow-Up,” European Urology, Vol. 58, No. 2, 2010, pp. 2007-2011. doi:10.1016/j.eururo.2010.04.027
[30] M. S. Wosnitzer and M. P. Rutman, “KTP/LBO Laser Vaporization of the Prostate,” Urologic Clinics of North America, Vol. 36, No. 4, 2009, pp. 471-483. doi:10.1016/j.ucl.2009.08.004

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.